We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+15.39%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.55B
AUM Growth
+$396M
Cap. Flow
+$31.1M
Cap. Flow %
0.88%
Top 10 Hldgs %
73.18%
Holding
30
New
2
Increased
6
Reduced
5
Closed
–

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$35.1M
2
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$7.62M
3
CDTX
Cidara Therapeutics
CDTX
+$7.01M
4
TSRO
TESARO, Inc.
TSRO
+$3.58M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$3.28M

Top Sells

Rank Stock Value
1
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$11.1M
2
PBYI icon
Puma Biotechnology
PBYI
+$7.06M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$5.8M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$5.67M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$2.54M

Sector Composition

Rank Sector Weight
1 Healthcare 86.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESPR
26
DELISTED
Esperion Therapeutics
ESPR
$20.2M 0.57%
908,542
– –
CLVS
27
DELISTED
Clovis Oncology, Inc.
CLVS
$18.5M 0.52%
528,188
-90,000
-15% -$5.8M
ACHN
28
DELISTED
Achillion Pharmaceuticals
ACHN
$13.8M 0.39%
1,279,340
– –
CDTX
29
DELISTED
Cidara Therapeutics
CDTX
$8.01M 0.23%
+23,334
New +$7.01M
TTPH
30
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$3.67M 0.1%
18,310
-55,796
-75% -$11.1M
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 9.56% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 0.35% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q4 2015 Portfolio in Review

As of Q4 2015, BB Biotech held 30 positions worth $3.55B, up 13% from $3.15B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

BB Biotech's Q4 2015 filing shows 2 new, 6 increased and 5 reduced positions. Its largest new stake was Sage Therapeutics: 708,663 shares worth $41.3M. The largest sale was Tetraphase Pharmaceuticals, Inc., an estimated $11.1M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 84% a quarter earlier.

  • BB Biotech's largest Q4 2015 buy was Sage Therapeutics: 708,663 shares worth $41.3M.
  • BB Biotech added most to Intercept Pharmaceuticals, Inc. in Q4 2015, an estimated $7.62M increase.
  • BB Biotech's biggest Q4 2015 reduction was Tetraphase Pharmaceuticals, Inc., cutting an estimated $11.1M.
  • BB Biotech's ten largest holdings make up 73% of its $3.55B portfolio in Q4 2015.
  • BB Biotech opened 2 new positions and closed 0 in Q4 2015.
  • BB Biotech's portfolio value rose 13% quarter-over-quarter to $3.55B.

Based on BB Biotech's 13F filing for Q4 2015, filed 9 Feb 2016.